ValiRx - ValiSeek Clinical Update, VAL401
VAL Tue, 16 Jan 2018, 07:10am GMT
ValiRx accelerates the development of treatments in cancer and women’s health to improve patient lives. We provide the scientific, financial and commercial framework to enable the rapid translation of innovative science into clinical development.
Industry: Health Care
Contact: +44 (0)2476 796496
Dr Suzy Dilly provides an update on the clinical progress and results of VAL401, the anti-cancer compound developed by ValiSeek, the joint venture between ValiRx and Tangent Reprofiling Limited. Further positive data has been released and shows that the VAL401 treatment has a measurable improvement on patient quality of Life, in addition to a positive impact on the disease.